Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy

Khreish F, Kochems N, Rosar F, Sabet A, Ries M, Maus S, Saar M, Bartholomä M, Ezziddin S (2021)

Publication Type: Journal article

Publication year: 2021

Journal

European Journal of Nuclear Medicine and Molecular Imaging Springer Verlag (Germany)

Book Volume: 48

Pages Range: 103-112

Journal Issue: 1

DOI: 10.1007/s00259-020-04828-5

Abstract

Purpose: Little is known about the efficacy of prostate-specific membrane antigen (PSMA)–targeted radioligand therapy (RLT) against liver metastases of metastatic castration-resistant prostate cancer (mCRPC). We retrospectively analyzed efficacy-related outcomes of 177Lu-PSMA-617 RLT in this setting and potential predictors of those outcomes. Methods: Twenty-eight consecutive mCRPC patients with liver metastases given 177Lu-PSMA-617 RLT were analyzed retrospectively. Their planned regimen was 4–6 cycles at 6 ± 2-week intervals; the mean activity/cycle was 6.5 ± 0.5 GBq. Hepatic response was determined by modified positron emission tomography response criteria in solid tumors; association of such response with overall survival (OS) was tested, as were relationships of the selected patient, disease, and treatment characteristics with hepatic progression-free survival (PFShep) and OS. Survival analyses used Kaplan–Meier curves, log-rank test at p < 0.05 significance, and Cox proportional-hazards modeling. Results: Median (minimum–maximum) follow-up was 37.5 (2.3–50.6) months. In liver metastases, complete or partial response was observed in 6 patients (21%) each, and stable disease in 1 (4%), for hepatic disease control in 46%. Overall, median (95% confidence interval) PFShep was 5.7 (2.2–9.2) months, and OS, 11.7 (3.0–20.4) months. Patients with hepatic disease control did not reach the median OS, while those with hepatic progressive disease had median OS (95% confidence interval) of 6.4 (1.6–11.1) months. In multivariate analysis, hepatic disease control by 177Lu-PSMA-617 RLT was significantly independently associated with OS, as was a prostate-specific antigen decline of ≥ 50% after 2 RLT cycles, and good baseline performance status (Eastern Cooperative Oncology Group 0–1). Hepatic tumor burden (≤ 25% vs. > 25% of liver volume) had no apparent relationship with hepatic tumor response, PFShep, or OS. Conclusion: 177Lu-PSMA-617 RLT frequently controlled liver metastases, resulting in long PFShep and significantly improved OS. Hepatic tumor burden appeared to lack any relationship with treatment efficacy, supporting 177Lu-PSMA-617 RLT of late-stage/end-stage mCRPC with liver metastases.

Involved external institutions

Universitätsklinikum des Saarlandes (UKS) DE Germany (DE) Goethe-Universität Frankfurt am Main DE Germany (DE)

How to cite

APA:

Khreish, F., Kochems, N., Rosar, F., Sabet, A., Ries, M., Maus, S.,... Ezziddin, S. (2021). Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy. European Journal of Nuclear Medicine and Molecular Imaging, 48(1), 103-112. https://doi.org/10.1007/s00259-020-04828-5

MLA:

Khreish, Fadi, et al. "Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy." European Journal of Nuclear Medicine and Molecular Imaging 48.1 (2021): 103-112.

BibTeX: Download